問卷

TPIDB > Principal Investigator

Principal Investigator


Far Eastern Memorial Hospital (在職)

Division of General Internal Medicine

Digestive System Department

National Taiwan University Hospital (在職)

Digestive System Department

Division of General Internal Medicine

National Taiwan University Hospital Hsin-Chu Branch

Digestive System Department

Digestive System Department

更新時間:2023-09-19

翁孟慈
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

41Cases

2025-08-01 - 2030-04-30

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-07-01 - 2027-11-30

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-02-01 - 2023-09-21

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-06-01 - 2025-03-28

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-07-01 - 2026-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-04-12 - 2028-12-31

Phase II

Active
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-1427 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)
  • Condition/Disease

    Moderately to Severely Active Ulcerative Colitis

  • Test Drug

    GS-1427

Participate Sites
8Sites

Recruiting8Sites

2024-02-01 - 2032-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2024-07-31 - 2035-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2017-01-22 - 2023-12-22

Phase III

Active
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis
  • Condition/Disease

    Ulcerative Colitis

  • Test Drug

    Filgotinib

Participate Sites
13Sites

Recruiting9Sites

Terminated3Sites

2023-02-01 - 2024-10-14

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

1 2 3 4 5